최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0114811 (2011-05-24) |
등록번호 | US-8633149 (2014-01-21) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 324 |
The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A meth
The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
1. A method for treating a breast condition in a subject, comprising: (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject;(b) determining the ER/PR status of said diseased breast tissue from said subject; and(c) based on the results of (a) and (b), admini
1. A method for treating a breast condition in a subject, comprising: (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject;(b) determining the ER/PR status of said diseased breast tissue from said subject; and(c) based on the results of (a) and (b), administering to a breast tissue of said subject, a first composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1,wherein said first composition is administered when the PAX2-to-DEFB 1 expression ratio is elevated and the ER/PR status is ER+/PR+ or ER+/PR−. 2. The method of claim 1, wherein said breast condition is breast cancer or MIN. 3. The method of claim 1, wherein said first composition comprises an antagonist of signal transducer and activator of transcription 3 (STAT3). 4. The method of claim 1, wherein said first composition comprises an anti-PAX2 agent conjugated to an antibody, a receptor or a ligand to target tumor tissue in said subject. 5. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-hormonal agent. 6. The method of claim 5, wherein the anti-hormonal agent is Tamoxifen. 7. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-ERBB-2/Her-2 agent. 8. The method of claim 7, wherein the anti-ERBB-2/Her-2 agent is trastuzumab. 9. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-AIB-1/SRC-3 agent.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.